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Pharm. Bull. 35 ( 2) In the field of tumor chemotherapy, "drug targeting" has recently been attempted to specifically kill tumor cells by conjugating a cytotoxic agent to a tumor-specific antibody in order to ensure the arrival of the agent at the tumor site.' 11) Such conjugates can be classified into the following three types: (i) a drug directly bond to an antibody; (ii) a drug bound to an antibody through a spacer; and (iii) a drug encapsulated in an antibody-bearing liposome. In the previous paper,11) we reported the effects of a monoclonal anti-carcinoembryonic antigen (CEA) antibody-ricin A-chain conjugate on human CEA-producing tumor cells in vitro and in vivo. We found that this conjugate did not show significant antitumor activity against solid tumors in vivo, mainly due to the rapid rupture of the linkage between ricin A-chain and the monoclonal antibody and the inactivation of the resulting free ricin A-chain in vivo. These results indicate the need for some measures such as encapsulation in liposomes to protect the biologically active substances to in vivo.
On the other hand, in the field of cancer therapy, various attempts are being made to enhance the response of hosts against tumors by the use of so-called biological response modifiers (BRM) including lymphokines.9,12 -14) Recent progress in biotechnology enabling these lymphokines to be obtained in relatively large amounts has facilitated research on the clinical application of these substances. However, if these substances are simply injected into tumor-bearing animals, they are generally not so effective because of dilution in the blood, degradation by various enzymes and so on. Therefore, it is important to develop a delivery system to ensure the arrival of sufficient amounts of these substances at the sites of tumors, and this system should also incorporate some means of protecting the factors from inactivation in vivo.
In this study, we prepared ricin-containing small unilamellar vesicles (SUV) and large unilamellar vesicles (LUV) bearing anti-CEA antibody on their surface and compared their effects on target cells as model experiments for the development of a delivery system for biologically active proteins, e.g. lymphokines, because the effect is easily discernable when these strongly toxic ricin-containing liposomes are tested against CEA-producing tumor cells. SUV were prepared by bath sonication for 2 to 3 h of toxin-containing multilamellar vesicles (MLV). For the preparation of toxin-containing MLV, a lipid mixture identical in composition to that used for the preparation of LUV was dried under vacuum onto the walls of a glass tube. Then 2 ml of a modified ricin A-chain solution (13 mg/ml) in PBS was added, the mixture was dispersed by vortex agitation, and the MLV preparation was centrifuged at 3000•~g for 20 min to remove free toxins. In some experiments, the lipid mixture used contained a trace amount of [3H]PC. Large vesicles were removed from the sonicated mixture by centrifugation at 100000•~g for 1 h. The SUV obtained were conjugated as above with thiolated antibody or reduced glutathione at 4•Ž overnight. The conjugated vesicles were then separated from unbound substances by chromatography on a column of Sepharose CL-6B which had been equilibrated with PBS. The fraction containing the conjugated SUV was passed through a 0.2 tim Millipore membrane. For determination of the amount of entrapped ricin, vesicles were prepared in the presence of
Binding Assay
The specific binding activity of the anti-CEA antibody-bearing toxin-liposomes was determined by the direct fluorescence test using liposomes in which fluorescein-labeled ricin was entrapped (Ab-FITC-lipo). Glutaraldehyde-fixed CEA-producing cells were incubated at 4•Ž for 1 h with Ab-FITC-lipo in PBS in the presence of lactose to prevent the binding of FITC-ricin that had leaked from the liposomes . After being washed with PBS to remove unbound Ab-FITC-lipo, the stained cells were observed under a fluorescence microscope .
Cytotoxic Vesicle Size Estimation A liposome mixture of AbT-LUV and AbT-SUV was separated by gel filtration on a column (2•~90 cm) of Sepharose CL-2B, and their sizes were determined by observation under an electronmicroscope after negative staining.
Cytotoxic Assay in Vivo Human CEA-producing cells, T3M-4 (5•~106 cells/mouse) were implanted into the subcutaneous space in the inguinal region of nude mice (BALB/c nu/nu) . The effect of antibody-bearing liposomes on tumor growth was evaluatea in terms of the area (mm2) of a tumor , calculated from its largest and smallest diameters.
Results

Coupling of SH-Antibodies to PDP-PE Liposomes
The series of reactions for the preparation of AbT-liposomes (AbTL) is schematically depicted in Fig. 1 . LUV (PC : cholesterol : PDP-PE = 9 : 10 : 1) were prepared by the reverse On the other hand, SUV could entrap less than 1% of the original ricin solution. Thiolated anti-CEA antibodies prepared as described in the experimental section contained an average of 1.8 SH groups/ molecule. The PDP-PE liposomes were reacted with freshly prepared SH-IgG (5 mg/ml) at 4 DC for 24 h. Then, the LUV suspension was centrifuged at 50000•~g for 1 h to remove unreacted SH-IgG. By measuring the absorbance of the supernatant at 343 nm, we calculated that the amount of SH-IgG coupled to the modified liposomes was about 30% of the total SHIgG employed in the coupling reaction. In the case of SUV after separation by Sepharose CL-2B column chromatography, the coupling efficiency for SH-IgG was about 40-50%.
Assay of Binding of AbTL to CEA-Producing Cells
Glutaraldehyde fixed CEA-producing cells (T3M-4 or C-1) or non-CEA-producing cells (A375) were incubated with Ab-FITC-lipo in 0.1 M lactose-PBS to prevent the binding of free FITC-ricin that had leaked from liposomes to the cells. The cells were washed and observed under a fluorescence microscope (•~400). Only CEA-producing cells were stained with the Ab-FITC-liposomes (Fig. 2) . Therefore, AbT-liposomes bind to CEA-producing cells through the specific antibodies on the surface, and not through nonspecific interaction of the liposomes with the cells. washed. The inhibition of [3H]leucine incorporation was assayed as described in the experimental section. Only anti-CEA-bearing ricin-containing LUV showed cytotoxicity toward the tumor cells, the other liposomes tested being not toxic at all (Fig. 4) . Ricin A-chain is a toxic subunit of ricin and shows toxic activity only in a cell-free system or when it is internalized by cells. From these results, it can be concluded that AbT-LUV are neither internalized by tumor cells nor fused with tumor cells.
Reversal of AbT-LUV Cytotoxicity by Lactose
Lactose is known to inhibit the cytotoxicity of ricin through inhibition of the binding of the ricin B-chain (a binding subunit) to the cell surface.26) In order to confirm that the cytotoxicity of AbT-LUV is due to the ricin released from them, HLC-2 cells were incubated with AbT-LUV at 37•Ž for 1 h, washed with the medium, and then suspended in the same medium containing lactose at various concentrations (0-50 mm), and the cell suspension was further incubated at 37•Ž for 48 h. As shown in Fig. 5 , lactose (17 mm) completely inhibited the cytotoxicity of AbT-LUV, suggesting that the cytotoxicity of AbT-LUV was actually due to ricin which was released into the microenvironment from AbT-LUV after specific binding of the AbT-LUV to the tumor cell surface.
Effects of Various Toxin-SUV on CEA-Producing Cells (T3M-4)
CEA-producing cells (T3M-4) or non-CEA-producing cells (A375) were incubated at 37•Ž for 48 h with two kinds of toxin-SUVs, anti-CEA-bearing ricin A-chain-containing SUV or glutathione bearing ricin A-chain-containing SUV, and then pulsed with [3H]leucine. As shown in Fig. 6 , tumor cytotoxicity was only seen when anti-CEA-bearing ricin A-chaincontaining SUVs were incubated with CEA-producing cells. Anti-CEA-bearing ricin A-chaincontaining SUV incubated with non-CEA-producing tumor cells, and glutathione-bearing ricin A-chain-containing SUV incubated with CEA-producing tumor cells had no effect on the tumor cells. 
Discussion
We reported in the previous paper11) the preparation of a conjugate between monoclonal anti,-CEA antibody and ricin A-chain, and its antitumor activity. However, the results in vivo were not so satisfactory. One of the reasons was confirmed to be the instability of the ricin Achain moiety of the conjugate.
On the other hand, many attempts have recently been made to attack tumors through the activation of the host's immunesystem with BRM, including lymphokines.9,12-14) However, direct administration of BRM to the host is generally not effective, partly due to dilution in the serum and partly due to destinction by various enzymes in vivo.
Our major aim in the preparation of monoclonal anti-CEA antibody-bearing ricincontaining liposomes was to analyze the interaction of those liposomes target cells, particularly with regard to the size of the liposomes, and to establish a model for BRMtargeting that would allow accumulation of a BRM at a sufficient concentration around tumor cells by using a monoclonal antibody as a carrier, with protection of the BRM from enzymic attack through its encapsulation in liposomes.
Since most BRM (including lymphokines) are proteins and a protein for such a model should be one whose effect is easily detectable, we encapsulated a strong cytotoxin, ricin, in LUV which were large enough to hold a considerable amount of the protein,25) and then bound anti-CEA antibody molecules to the surface of the liposomes. After these modifi- The experimental details are given in the text.
cations, the activities of both the antibody on the liposome surface and ricin in the liposomes were ascertained to be retained, because AbT-liposomes bound to CEA-producing cells specifically and killed them effectively in vitro (Figs. 2 and 3) . We also prepared anti-CEAbearing LUV with entrapped ricin A-chain, a toxic subunit of ricin, but they did not show cytotoxicity toward CEA-producing cells (Fig. 4) . Moreover, the cytotoxicity of the AbT-LUV with entrapped ricin was found to be inhibited by lactose, which is an inhibitor of ricin (Fig. 5) .
On the basis of these results, the mechanism of the cytotoxicity of AbT-liposomes may be explained as follows: i) AbT-LUV bind to CEA moieties on the target cell surface; ii) the AbT-LUV burst on the tumor cell surface, releasing ricin; iii) the released ricin binds to the nearest tumor cell; and iv) the bound ricin is internalized by the tumor cell and kills it. In conclusion, AbT-LUV exert their cytotoxicity through increasing the toxin concentration around the tumor cells, i.e., not through fusion or internalization.
On the other hand, AbT-SUV containing ricin A-chain can kill CEA-producing cells (Fig. 6) , indicating that the ineffectiveness of AbT-LUV containing ricin A-chain is not due to the absence of B-chain. This also suggests that AbT-SUV are internalized by tumor cells, unlike AbT-LUV. This difference between LUV and SUV may be due to the difference in their diameters. The diameter of AbT-LUV was found to be about four times greater than that of AbT-SUV. There may be a threshold as to the size of liposomes for internalization into cells. The internalization of AbT-SUV was most probably effected by endocytosis, not by fusion, because AbT-LUV with the same lipid composition as AbT-SUV could not be internalized. Matthay et al.27 ) also confirmed that small liposomes were pinocytosed more effectively, while larger liposomes could associated with the cell surface but were not subsequently internalized. Other investigators came to the same conclusion. 8, 28) Therefore, if we want to deliver drugs into cells directly, we have to use SUV, but if it is sufficient to produce an enhanced concentration of drugs around cells, we can use LUV. Various low-molecular-weight antitumor metabolic inhibitors should be suitable for delivery in SUV, while various BRM (including lymphokines) may be effectively delivered by means of LUV.
Considering that a large amount of liposomes is trapped in the reticuloendothelial system (kidneys, liver, etc.), BRM which activate immunocytes are more suitable than chemotherapeutic agents or cytotoxins as substances for entrapment in liposomes. The antitumor effects of antibody-bearing liposomes with various entrapped lymphokines in vivo are now under study in our laboratory.
